Publications by authors named "Laurie Sherman"

Article Synopsis
  • The study focuses on patients with lower-risk myelodysplastic syndromes (LR-MDS) who depend on red blood cell transfusions and are either not responding to current treatments or are ineligible for them, particularly erythropoiesis-stimulating agents (ESAs).
  • It involves a phase 3 clinical trial comparing the effectiveness of imetelstat (a telomerase inhibitor) to a placebo in achieving red blood cell transfusion independence, involving 178 participants across various countries.
  • The primary goal was to measure the percentage of patients who went at least 8 weeks without needing transfusions after starting treatment, with results from this study expected to provide insights into a potential new treatment
View Article and Find Full Text PDF
Article Synopsis
  • * The phase III trial, IMpactMF, will compare imetelstat to the best available therapies (excluding JAK inhibitors) in these refractory MF patients.
  • * The trial will administer imetelstat via IV every 21 days, focusing on overall survival as the main goal, while also examining additional effects such as symptom relief, spleen size, and safety.
View Article and Find Full Text PDF
Article Synopsis
  • Myelofibrosis patients who don't respond to JAK inhibitors have a poor survival rate of about 13-16 months; a phase II study was conducted to evaluate the telomerase inhibitor imetelstat in these patients.
  • In this study, patients received either 9.4 mg/kg or 4.7 mg/kg of imetelstat to assess responses in spleen size reduction and symptom improvement, with results showing better outcomes for the higher dose.
  • The higher dose (9.4 mg/kg) led to a median overall survival of 29.9 months and significant benefits in symptom relief, despite common side effects like reversible cytopenias, prompting further phase III studies.
View Article and Find Full Text PDF
Article Synopsis
  • - This study focuses on using Imetelstat, a drug that inhibits telomerase, for treating patients with lower-risk myelodysplastic syndromes (MDS) who depend on red blood cell (RBC) transfusions and have not responded well to previous treatments.
  • - In a phase II/III trial, 57 patients were treated, showing 37% had RBC transfusion independence (TI) after 8 weeks and 23% after 24 weeks, with median TI lasting about 65 weeks overall, and even longer in a specific subgroup.
  • - The findings suggest Imetelstat not only helps reduce reliance on transfusions but also appears to impact the malignant cells associated with the disease, with
View Article and Find Full Text PDF

Background: Operating room (OR) fires are a preventable danger. Our aim is to examine the effectiveness of OR fire simulation scenarios as a supplement to classroom-based training for managing OR fires.

Methods: Eighty-two participants were randomly divided into 14 groups.

View Article and Find Full Text PDF

Purpose: Foretinib is an oral multikinase inhibitor targeting MET, VEGF, RON, AXL, and TIE-2 receptors. Activating mutations or amplifications in MET have been described in patients with papillary renal cell carcinoma (PRCC). We aimed to evaluate the efficacy and safety of foretinib in patients with PRCC.

View Article and Find Full Text PDF

Foretinib is an oral multi-kinase inhibitor targeting MET, vascular endothelial growth factor receptor (VEGFR)-2, RON, KIT, and AXL kinases. In this Phase 1, open-label, non-randomized study, foretinib was administered once daily at doses of 60 mg, 80 mg, 100 mg, or 120 mg for 28 days. The primary objectives were to determine the maximum tolerated dose (MTD) and assess the safety and tolerability of the daily oral administration schedule.

View Article and Find Full Text PDF

Background: Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-lived. In previous trials, MEK inhibition appeared to be promising in this population.

View Article and Find Full Text PDF

Purpose: Foretinib is an oral multikinase inhibitor targeting Met, RON, Axl, and vascular endothelial growth factor receptor. We conducted a phase I, first-time-in-human, clinical trial using escalating doses of oral foretinib. The primary objectives are to identify a maximum tolerated dose and determine the safety profile of foretinib.

View Article and Find Full Text PDF

This study evaluated the effect of hepatic impairment on the pharmacokinetics of sunitinib and its active metabolite, SU12662. This open-label study enrolled subjects with normal hepatic function (n = 8), mild (Child-Pugh [CP]-A; n = 8), or moderate (CP-B; n = 8) hepatic impairment. Subjects received sunitinib 50 mg as a single oral dose.

View Article and Find Full Text PDF

The effect of food on the oral bioavailability of sunitinib malate (SU11248, an oral, multi-targeted tyrosine kinase inhibitor with anti-angiogenic and anti-tumor activities) was assessed in a randomized open-label, two-way crossover study. A 50-mg dose of SU11248 was administered to 16 healthy subjects after a 10-h fast in one period and after a high-fat, high-calorie meal in the other period. The 90% confidence intervals (CIs) for maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC) were within the 80-125% bioequivalence range, indicating the absence of a food effect.

View Article and Find Full Text PDF